es, with and without hepatorenal syndrome. Rev Med Chil
2002;130:173-180
4 Arroyo V. Reviewarticle: hepatorenal syndrome-how to assess response to treatment and nonpharmacological therapy.
Aliment Pharmacol Ther 2004;20 (Suppl 3):49-54
5 Anand R, Harry D, Holt S, Milner P, Dashwood M, Goodier D, Jarmulowicz M, Moore K. Endothelin is an important
determinant of renal function in a rat model of acute liver and renal failure. Gut 2002;50:111-117
6 Ming Z , Smyth DD, Lautt WW. Decreases in portal flow trigger a hepatorenal reflex to inhibit renal sodium and water
excretion in rats: role of adenosine. Hepatology 2002;35:167-175
7 Farzaneh-Far R, Moore K. Cysteinyl-leukotrienes and the liver. Prostaglandins Other Lipid Mediat 2003;72:35-50
8 Capella GL. Anti-leukotriene drugs in the prevention and treatment of hepatorenal syndrome. Prostaglandins Leukot
Essent Fatty Acids 2003;68:263-265
9 Turkay C, Yonem O, Arikan O, Baskin E. Nitric oxide and renal functions in liver cirrhosis. Turk J Gastroenterol
2004;15:73-76
10 Gulberg V, Moller S, Henriksen JH, Gerbes AL. Increased renal production of C-type natriuretic peptide (CNP) in patients
with cirrhosis and functional renal failure. Gut 2000;47:852-857
11 Uriz J, Gines P, Ortega R, Jimenez W, Cardenas A, Calahorra B, Sort P, Fernandez J, Bataller R, Arroyo V, Rivera F,
Rodes J. Increased plasma levels of neuropeptide Y in hepatorenal syndrome. J Hepatol 2002;36: << 上一页 [11] [12] [13] 下一页
|
